<DOC>
	<DOCNO>NCT00814073</DOCNO>
	<brief_summary>The objective study compare safety efficacy masitinib ( AB1010 ) placebo patient mastocytosis handicap .</brief_summary>
	<brief_title>A Phase 3 Study Compare Efficacy Safety Masitinib Placebo Treatment Patients With Smouldering Systemic , Indolent Systemic Cutaneous Mastocytosis With Handicap</brief_title>
	<detailed_description>Mastocytosis disease characterize mast cell invasion various organ . Mast cell bone marrow derive cell produce histamine substance cause allergic anaphylactic reaction . Accumulation mast cell body organs inhibit functionality organ eventually cause degeneration . Mutations mast cell growth factor receptor ( KIT protein , product c-Kit proto-oncogene ) might find patient mastocytosis . Masitinib ( AB1010 ) tyrosine kinase inhibitor ( TKI ) , selectively effectively inhibit c-kit . Its effect may include inhibition cell proliferation , inhibition cell cycle progression induction apoptosis result reduction mast cell accumulation body tissue . This drug thereby specific mastocytosis active slow reduce number mast cell particularly aggressive form disease .</detailed_description>
	<mesh_term>Mastocytosis</mesh_term>
	<mesh_term>Mastocytosis , Systemic</mesh_term>
	<mesh_term>Mastocytosis , Cutaneous</mesh_term>
	<mesh_term>Mastocytoma</mesh_term>
	<criteria>1 . Patient one follow document mastocytosis per WHO classification : Smouldering Systemic Mastocytosis , Indolent Systemic Mastocytosis , Cutaneous Mastocytosis 2 . Patient document mastocytosis evaluable disease base upon histological criterion : typical infiltrates mast cell multifocal diffuse pattern skin and/or bone marrow biopsy 3 . Patient document treatment failure his/her handicap ( ) least one follow therapy use optimize dose : Anti H1 , Anti H2 , Proton pump inhibitor , Osteoclast inhibitor , Cromoglycate Sodium , Antileukotriene 4 . Handicapped status define least two follow handicap , include least one among pruritus , flush , depression asthenia : pruritus score ≥ 6 , number flush per week ≥ 7 , Hamilton rating scale ( depression ) ≥ 10 , number stool per day ≥ 4 , number mictions per day ≥ 8 , Fatigue Impact Scale total score ( asthenia ) ≥ 40 5 . Patients OPA &gt; 2 ( moderate intolerable general handicap ) 6 . Male female patient age ≥ 18 year 1 . Patient one follow mastocytosis : Systemic Mastocytosis Associated clonal Hematologic Non Mast cell lineage Disease ( SMAHNMD ) , Mast cell leukemia ( MCL ) , Aggressive systemic mastocytosis ( ASM ) 2 . Previous treatment Tyrosine Kinase Inhibitor 3 . Patient present least one follow feature : ischemic heart disease , cardiac failure , conduction disorder arrythmia 4 . Patient condition physician judge could detrimental subject participate study ; include clinically important deviation normal clinical laboratory value concurrent medical event Previous treatment 5 . Change symptomatic treatment mastocytosis administration new treatment mastocytosis within 4 week prior baseline 6 . Treatment investigational agent within 4 week prior baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Mastocytosis handicap</keyword>
	<keyword>Mastocytosis</keyword>
	<keyword>Smouldering systemic mastocytosis</keyword>
	<keyword>Indolent systemic mastocytosis</keyword>
	<keyword>Cutaneous mastocytosis</keyword>
	<keyword>Mast cell</keyword>
	<keyword>Mast cell infiltration</keyword>
	<keyword>Skin</keyword>
	<keyword>Bone marrow</keyword>
	<keyword>Pruritus</keyword>
	<keyword>Flushes</keyword>
	<keyword>c-kit</keyword>
	<keyword>c-kit mutation</keyword>
	<keyword>Wild Type</keyword>
	<keyword>Mutation Asp-816-Val ( D816V )</keyword>
</DOC>